Brian Kim, MD: Pushing Dermatology Forward and Alys Pharmaceuticals
Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.
Stay updated with breaking news from Brians Kim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
<p style="text-align:justify">Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of <em>non-small cell lung cancer (</em>NSCLC)<em>. </em> And in an early parallel study in humans, combining immunotherapy with dupilumab<em>—</em>an <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2018.00888/full" target="_blank">Interleukin-4</a> (IL-4) receptor-blocking ant...
The Paul G. Allen Frontiers Group, a division of the Allen Institute, today announced the launch of the Allen Discovery Center (ADC) for Neuroimmune Interactions at the Icahn School of Medicine at Mount Sinai.
There’s a reason it feels so maddeningly good.